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The recent discovery that vitamin E (VE) regulates gene activity at the transcriptional level indicates that VE may exert part of its
biological effects by mechanisms which may be independent of its well-recognised antioxidant function. The objective of this study was the
identification of hepatic vitamin E-sensitive genes and examination of the effects of VE on their corresponding biological endpoints. Two
groups of male rats were randomly assigned to either a VE-sufficient diet or to a control diet deficient in VE for 290 days. High-density
oligonucleotide microarrays comprising over 7000 genes were used to assess the transcriptional response of the liver. Differential gene
expression was monitored over a period of 9 months, at four different time-points, and rats were individually profiled. This experimental
strategy identified several VE-sensitive genes, which were chronically altered by dietary VE. VE supplementation down-regulated scavenger
receptor CD36, coagulation factor IX and 5-a-steroid reductase type 1 mRNA levels while hepatic gamma glutamyl-cysteinyl synthetase was
significantly up-regulated. Measurement of the corresponding biological endpoints such as activated partial thromboplastin time, plasma
dihydrotestosterone and hepatic glutathione substantiated the gene chip data which indicated that dietary VE plays an important role in a
range of metabolic processes within the liver.
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1. Introduction macrophages [3], the hepatic a-tocopherol transfer proteinVitamin E (VE) is considered the most effective lipid-
soluble, chain-breaking antioxidant, which protects cell
membranes from peroxidative damages [1]. Since its dis-
covery, studies have mainly focused on its antioxidant
properties. In 1991 Angelo Azzi’s group first described
non-antioxidant, cell signalling functions of VE demonstrat-
ing that a-tocopherol regulates protein kinase C activity in
smooth muscle cells [2]. At the transcriptional level, a-
tocopherol modulates the expression of the CD36 scavenger
receptor in smooth muscle cells and monocyte-derived0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2004.02.002
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2628.
E-mail address: rimbach@foodsci.uni-kiel.de (G. Rimbach).(aTTP) [4] as well as the expression of liver collagen alpha-
1 [5], collagenase [6] and the a-tropomyosin gene [7].
Recently, a tocopherol-dependent transcription factor (to-
copherol associated protein, TAP) has been identified [8].
Methods for the large-scale measurement of gene expres-
sion are becoming important tools in the field of free radical
research and molecular nutrition [9–12]. In order to obtain a
comprehensive understanding of the molecular mechanisms
of action of VE, a global gene expression profile in rat liver
was obtained using gene chip technology. Various time-point
measurements were introduced in the experimental design in
order to elucidate whether or not differences in the gene
expression profile were manifested consistently over a pro-
longed period of time. In previous studies, differential
changes in gene expression in response to oxidant/antioxi-
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[13] and in pooled samples [14]. To the best of our knowledge
the current study contains a novel design: with animals
followed for a period of 9 months at four individual time-
points and animals profiled individually at each time-point.
Furthermore, changes in gene expression were tested for their
ability to cause alterations in the corresponding biological
endpoints. Our choice of tissue was guided by the fact that the
liver, as the central organ involved in endogenous VE
metabolism, is highly susceptible to changes in dietary VE
with potential ‘‘down-stream’’ effects on extrahepatic tissues.2. Materials and methods
2.1. Animal and diets
Two groups of 30 recently weaned male albino rats (Fisher
344, Charles River) with an initial average weight of 50–60 g
were randomly assigned to either a vitamin E-containing diet
(VE+) [15] or to a control, vitamin-deficient diet (VE-) for 290
days. The VE+ diet contained 60 mg/kg RRR-a-tocopheryl
acetate (Vitamin E acetate 950 NS, Roche Vitamins Ltd,
Basel, Switzerland) which corresponds to 80 IU/kg diet. The
current recommendation for vitamin E by the American
Institute of Nutrition is 75 IU/kg in the maintenance diet for
growing rats [16]. The VE- animals received 60 mg/kg of the
Vitamin E acetate-free 950 NS vehicle (16% fish gelatine, 8%
micro gel E, 1% Sipernat 50) resulting in a final dietary
concentration of 1.7 mg/kg RRR-a-tocopheryl acetate. The
VE and VE+ rats consumed the diets ad libitum and had free
access to water. Rats were maintained under standard con-
ditions at 22F 1 jC with 12:12-h dark/light cycles. The
Laboratory Animal Care Committees of F. Hoffmann-La
Roche Ltd, Basel and the Veterinary Office of Basel-Stadt,
Switzerland approved all animal protocols.
Beginning from day 17 of feeding, five animals per
group were euthanized every 3 months under isoflurane
anaesthesia by withdrawing blood from the vena cava.
Livers were removed, rinsed in ice-cold phosphate-buffered
saline, pH 7.4 and snap frozen in liquid nitrogen. Samples
were stored at  80 jC prior to RNA extraction.
2.2. Vitamin E status in liver and plasma pyruvate kinase
activity
Liver tissue was saponified in a methanolic potassium
hydroxide solution. The solution was diluted in 35% ethanol
and extracted with hexane/toluol. a-Tocopherol was quan-
tified by isocratic HPLC analysis [17] using a Lichrosorbk
Si 60.5 Am, 20  4 mm pre-column coupled to a
Lichrosorbk Si 60, 5 Am, 125 4 mm column (Stagroma,
Reinach, Switzerland) and 3% 1.4-dioxane in n-hexane as
the mobile phase (flow rate f 1.6 ml/min, pressure 35–55
bar). Fluorescence was measured at 330 nm after excitation
at 295 nm.The plasma samples were analysed for a-tocopherol
using a routine HPLC method. [18]. Briefly, the plasma
proteins were precipitated using ethanol and tocopherol was
extracted by liquid/liquid extraction with hexane. After
centrifugation, an aliquot of the organic phase was chroma-
tographed isocratically on a normal phase HPLC system.
Tocopherol was identified and quantified by fluorimetry
(excitation at 298 nm/emission at 326 nm). For quality
control, internal control samples were analyzed. The control
samples analyzed within each HPLC run indicated that the
measured values were within the range of the declared
concentrations of the certified samples. Pyruvate kinase
(PK) was analyzed in Li-heparinized plasma using a
‘‘COBAS-Fara II’’ centrifugal analyzer as described else-
where [15].
2.3. Total RNA extraction, cRNA preparation and gene chip
hybridisation
Snap frozen tissue samples were homogenized under
liquid nitrogen. RNA isolation was performed using phe-
nol–chloroform extraction (TRIzol Reagent, Invitrogen,
Basel, Switzerland). Phenol–chloroform-purified RNA
was repurified using RNeasy mini spin columns (Qiagen,
Basel, Switzerland) and DNase-digested on the columns
(RNase-Free DNase Set, Qiagen) according to the manu-
facturer’s description.
A T7-(T)24 primer (5V-GGCCAGTGAATTGTAATAC-
GACTCACTATAGGGAGG CGG-(dT)24-3V) was annealed
to 10 Ag of total RNA and Superscript II reverse transcrip-
tase (400 U) was utilized to synthesize first-strand cDNA in
the presence of DTT, dNTPs and 1 reaction buffer. Sec-
ond strand synthesis was performed by adding E. coli DNA
polymerase I (40 U), E. coli ligase (10 U), and RNase H (2
U) in a final reaction containing 1 second strand buffer in
the presence of dNTPs. Finally, strands were blunted using
T4 DNA polymerase (10 U) (Superscriptk Microarray
Customized Kit, Invitrogen). The resulting cDNA was
purified by phenol/chloroform extraction and, subsequently,
in vitro transcription was carried out for 3 h using T7 RNA
polymerase (Megascriptk T7 Kit, Ambion, Texas, USA),
incorporating bio-16-UTPs and bio-11-CTPs (Roche Mo-
lecular Biochemicals, Penzberg, Germany). After RNeasy
purification, 10 Ag of the resulting cRNA was fragmented
using 40 mM Tris acetate (pH 8.1), 100 mM potassium
acetate and 30 mM magnesium acetate at 95 jC for 35 min.
The hybridisation mixture was prepared to contain 100 mM
MES buffer, 1 M NaCl, 20 mM EDTA, 0.01% Tween 20,
sample cRNA, fragmented bacterial control spikes, the
biotinylated oligo 984, herring sperm DNA (0.5 Ag/Al;
Invitrogen) and acetylated BSA (0.25 Ag/Al; Promega) as
described in the Affymetrix GeneChipR Expression Anal-
ysis Technical Manual. Samples were then hybridised onto
Affymetrix GeneChipR Rat Genome U34A arrays for 16
h at 45 jC, with a separate gene chip used for each
individual animal. Finally, arrays were washed in the
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EukGE-WS2v3 program and staining was carried out twice
with streptavidin R-phycoerythrin (SAPE) using an anti-
body amplification protocol. Raw fluorescence data were
collected by confocal laser scanning (Hewlett Packard, Palo
Alto, CA, USA) and analysed with the AffymetrixR Micro-
array Suite (MAS 4.0).
2.4. GeneChipR microarray expression analysis
Data processing was carried out using the RACE-A
analysis tool (Roche Bioinformatics, Basel, CH). The arrays
were normalized against the mean of the total sum of
Average Difference (AvgDiff) values across all arrays used.
Mean average difference values (MeanAvgDiff) were cal-
culated from the replicate samples. Possible outliers were
identified using the procedure of Nalimov with a 95%
confidence interval. Subsequently change factors (Chgf)
for each individual gene were calculated among the different
treatment groups using pairwise comparisons and statistical
significance was assessed by Student’s t test with prior
testing for the normal distribution of the data. For a
comprehensive analysis, genes with a maximal MeanAvg-
Diff>20 and differential change fold expression (Chgf) of
>0.25; < 0.25 (>25% increase or >25% decrease) com-
bined with a significance level of P < 0.05 were selected.
Differential expression profile analysis between the two
treatment groups was performed at four different time-points
(T1 = day 17, T2 = day 91, T3 = day 191, T4 = day 269 of
feeding) over the 9-month study period. Data obtained
during the different time-points have been compared and
only genes consistently up- or down-regulated over a period
of time >170 days (3 consecutive time-points) have been
taken into consideration for further characterization.
2.5. Plasma testosterone and 5a-dihydrotestosterone levels
Heparinized plasma was collected and stored at  80 jC.
Quantification of testosterone and 5a-dihydrotestosterone
(5a-DHT) was performed by using a Coat-A Count Total
Testosterone (DPC, Los Angeles, USA) and a 5a-DHT
ELISA kit (IBL, Hamburg, Germany), respectively, accord-
ing to the manufacturer’s protocol.
2.6. Activated partial thromboplastin time
For measurement of activated partial thromboplastin time
(APTT), blood was collected by puncture of the retro orbital
vein under light isofluorane anesthesia. The first five free
flowing blood drops were discarded. Thereafter, 9 volumes
of blood were immediately mixed with 1 volume of 0.13 M
sodium citrate and centrifuged at 2000 g for 30 min. The
separated plasma was stored in the refrigerator at + 4 jC
until analysis. Fifty microliters of plasma was incubated
with 50 Al actin FSL reagent (Dade Behring #B4219-2,
Marburg, Germany) at 37 jC for 180 s. The reaction wasstarted by adding 50-Al CaCl2-solution (Dade Behring
#ORHO 33) and the clotting time recorded using a
ball type coagulometer (Amelung KC 4A micro, Lemgo,
Germany).
2.7. Plasma triglycerides, total cholesterol and glucose
Heparinized plasma was collected and stored at  80 jC.
Quantification of triglycerides, total cholesterol and glucose
was performed by using a Hitachi 912 analyser (Roche
Diagnostics GmbH, Mannheim, Germany), according to the
manufacturer’s protocols.
2.8. Glutathione analysis
Glutathione (GSH) and glutathione disulfide (GSSG) in
liver homogenates were measured by HPLC with UV
detection [19]. Liver tissue was homogeneized in ice-cold
PBS. One hundred microliters of liver homogenate was
added to an equal volume of trichloroacetic acid 5% con-
taining 0.1 mM desferal and centrifuged at 4000 g for 10
min at 4 jC. Fifty milligrams of NaHCO3 and 50 Al freshly
prepared iodo-acetic acid (108 mM) were added to the
sample, vortexed and incubated in the dark for 1 h. After
adding 200 Al of Sanger reactant (2,4-dinitro-1-fluoroben-
zene in 0.375% ethanol), samples were vortexed and let for
reaction over night in the dark at room temperature. After
reaction samples were centrifuged at 2000 g for 10 min at
4 jC, the supernatant was collected, filtered and injected in
the HPLC system using the following conditions. Injection
volume: 100 Al, flow: 1.2 ml/min, solvent A: 25% methanol
in water and solvent B: 2 M sodium acetate/methanol
(36:64, pH 4.6), the column was a Waters Spherisorb
NH2, 5 Am (15 0.46 cm), the elution gradient: from
75% A to 95% B in 30 min, and the detection wave length
was 365 nm.
2.9. Statistical analysis
Data are presented as meanF standard error of the mean
(S.E.). The data were checked for normality and log-trans-
formed where appropriate. Statistical analysis was carried
out using ANOVA and Student t tests (SPSS for Windows
version 10.0). Differences were considered significant if
P < 0.05.3. Results
Feed intake was not significantly different between the
two experimental groups. Furthermore, body weight gain
was similar between VE and VE+ animals within the 9-
month experimental trial as shown in Table 1. Rats fed the
VE+ diet exhibited significantly higher plasma VE levels
and significantly lower plasma pyruvate kinase activities as
compared to controls receiving the VE diet. Differences in
Table 1
Effect of dietary vitamin E on body weight gain, plasma vitamin E and plasma pyruvate kinase activity as well as liver vitamin E concentrations in rats at
various time points (T1–T4)
Body weight (g) Plasma vitamin E (Amol/l) Plasma pyruvate kinase (U/ml) Liver vitamin E (nmol/g tissue)
VE VE+ VE VE+ VE VE+ VE VE+
T1 (Day 17) 124.8F 4.60 124.2F 3.93 3.20F 0.19 18.1*F 1.52 2.36F 0.05 2.28F 0.11 2.08F 2.24 44.95*F 14.95
T2 (Day 91) 321.7F 2.32 325.2F 6.70 0.20F 0.04 31.6*F 1.34 24.4F 0.84 1.80*F 0.08 1.75F 1.53 71.52*F 13.45
T3 (Day 191) 354.7F 15.2 352.5F 18.91 0.53F 0.09 21.6*F 1.92 12.4F 2.28 1.47*F 0.09 1.34F 0.50 82.93*F 14.8
T4 (Day 269) 387.2F 8.94 388.4F 11.85 0.20F 0.09 27.4*F 3.17 18.7F 0.80 1.90*F 0.26 0.35F 0.20 83.91*F 15.86
Values are group meansF S.E., n= 5. At T0 average BW: 60F 4 g, plasma VE and plasma PK as well as liver VE were not determined.
* Indicates significant differences of P< 0.05 between the two treatment groups.
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ences in hepatic VE concentrations. Liver VE levels in-
creased time-dependently in the VE+ group.Fig. 1. Effect of dietary vitamin E on hepatic regulatory subunit gamma-glutamylcy
(FIX) and 5-a-steroid reductase type 1 (5a-R1) mRNA levels in rat liver mea
*Significant differences ( P< 0.05) between VE- and VE+ rats within one time poOut of the f 7000 genes represented on the GeneChipR,
only 14 annotations comprising five genes (1 gamma-
glutamylcysteinyl synthetase, 1GSH synthetase, 1 fac-steinyl synthetase (g-GCS), scavenger receptor CD36, coagulation factor IX
sured at four different time-points. Values are group meansF S.E., n= 5;
int. T1 = day 17, T2 = day 91, T3 = day 191 and T4 = day 269 of feeding.
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receptor CD36) and seven expressed sequence taqs were
consistently differentially expressed in response to VE in at
least three consecutive time-points. The regulatory subunit
of gamma-glutamylcysteinyl synthetase (g-GCS), scaven-
ger receptor CD36, 5-a-steroid reductase type 1 (5a-R1)
and coagulation factor IX (FIX) were followed up in more
detail. We have selected these four genes since their gene
products are well characterized and metabolic endpoints are
available in order to confirm whether differences in mRNA
levels were associated with any ‘down-stream’ functional
changes.
The time course of the gene expression profiles of g-
GCS, CD36, FIX and 5a-R1, over the 9-month experimen-
tal period is given in Fig. 1. At T1 there were no significant
differences between VE+ and VE rats for any of these four
genes. However, between T2 and T4 a consistent up-
regulation (g-GCS) and down-regulation (CD36, FIX and
5a-R1), respectively, was evident in VE+ animals as com-
pared to controls.Fig. 2. Effect of dietary vitamin E on liver Glutathione levels (A), partial
thromboplastin time (B) and plasma normalised 5a-dihydrotestosterone
(5a-DHT/testosterone ratio) (C) in rats. Values are group meansF S.E.,
n= 5; *Significant differences ( P < 0.05) between VE and VE+ rats at T4.Subsequently, differences in the gene expression levels
observed by GeneChipR technology were confirmed by
real-time PCR (data not shown) and substantiated by func-
tional parameters. VE+ rats exhibited 20% higher hepatic
GSH levels as compared to VE rats (Fig. 2A), whereas
liver GSSG levels (VE = 25.1F 7.1 nmol/g vs. VE+ =
28.2F 3.1 nmol/g) remained largely unchanged. As sum-
marized in Fig. 2B, a significant decrease in FIX mRNA
levels in VE+ rats was accompanied by a significant increase
in activated partial thromboplastin time APTT. Furthermore,
rats receiving the VE+ diets showed a significant decrease in
plasma normalised 5-a-dihydrotestosterone (5a-DHT/tes-
tosterone ratio) as compared to VE animals (Fig. 2C).
Since the biological function of liver CD36 has not yet been
fully established, we based our endpoint analyses on find-
ings made in CD36-deficient mice [20,21] and humans with
non-functional CD36, where plasma lipids, triglycerides,
free fatty acids and glucose levels were altered [22].
However, under the conditions investigated, changes in
CD36 gene expression were not accompanied by any
significant differences in plasma triglycerides, total choles-
terol and fasting glucose (data not shown).4. Discussion
Our experimental design monitoring differential gene
expression at four individual time-points over a period of 9
months with each rat profiled individually allowed chronic
changes in mRNA levels in response to dietary VE to be
monitored. It is of interest to note that under in vivo
conditions, changes in differential gene expression are
rather small and often below 2 [23,24], a threshold factor
often used in cell culture experiments. Interestingly after
17 days (T1) the mRNA levels of g-GCS, CD36, 5a-R1
and FIX were similar between VE and VE+ animals.
However, these transcripts were consistently altered be-
tween T2 (day 91) and T4 (day 269). Fischer et al. [13]
reported that dietary VE deficiency over a 7-week period
in rats did not result in any significant changes in the gene
expression profile among 465 liver genes monitored with a
DNA micro-array. On the basis of these and the current
data, it seems likely that only long-term changes in VE
exposure result in substantial and consistent changes in
gene expression. Of particular interest is the variety of
biological pathways which seem to be influenced by VE.
The potential links between VE and androgen metabolism,
blood coagulation and redox homeostasis are already
known although the molecular mechanisms have not been
elucidated. The present study contributes to the current
understanding of the mechanisms of action behind these
observations.
Plasma levels of vitamin E were used to evaluate the
adequacy of the supplementation in the present study. With
an average plasma VE concentration of 26 Amol/l over the
last three time points (T2–T4), the VE levels measured in
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in healthy humans not supplemented with VE [25].
Pyruvate kinase activity is an indicator for vitamin E
deficiency. However, the correlation between PK activity
and degree of VE deficiency is a matter of debate. PK is
released by damaged erythrocytes as well as myocytes and
many more cell types. The observed differences in PK
activity at day 17 (VE group) is essentially caused by an
increased hemolysis of red blood cells. Hemolysis is known
to be an early indicator of mild VE deficiency [26]. With
ongoing, more profound VE depletion, PK is also released
by damaged myocytes (time T2–T4). The classical signs of
severe VE deficiency such as Ataxia and body weight loss
were not observed during the 290 days of differential VE
supplementation.
4.1. Gamma-glutamyl cysteinyl synthetase
De novo synthesis of GSH from its constitutive amino
acids glutamate, cysteine, and glycine involves two sequen-
tial reactions. The first is catalysed by g-GCS and is rate-
limiting, and the second by GSH synthetase [27]. VE
supplementation resulted in a significant up-regulation of
the expression of g-GCS as well as GSH synthetase (data
not shown). It has been previously demonstrated that dietary
VE increased GSH levels in rat liver [28]. Thus, the
augmentation of cellular GSH by VE may offer an impor-
tant dietary strategy to enhance the ability of the liver to
cope with oxidative stress. The importance of intracellular
GSH in preventing apoptosis [29] and inflammation [30]
has been appreciated for a long time and both the dietary
and pharmacological manipulation of GSH synthesis have
received much attention. Increased levels of GSH in the
liver have been associated with increased tolerance to
oxidative stress and to xenobiotics [31]. In vitro experiments
have demonstrated a synergism between GSH and VE,
indicating that GSH can recycle VE radicals [32,33] via
ascorbic acid. The current findings suggest an alternative
pathway and a novel molecular mechanism of VE/GSH
interactions within the so-called cellular antioxidant net-
work [34,35], i.e. that VE up-regulates GSH synthetase and
g-GCS. It has been reported that g-GCS mRNA levels
decline with age in the liver [36] and that dialysis patients
who are exposed to high oxidative stress show low concen-
tration of GSH [37]. Further studies investigating whether
dietary VE supplementation can delay or prevent the age-
related or oxidation-related decline in g-GCS are therefore
merited.
4.2. Scavenger receptor CD36
Alpha-tocopherol exposure in human monocyte cell lines
and primary monocyte derived macrophages has been
shown to decrease CD36 expression and decrease the extent
of modified low density lipoprotein (LDL) accumulation.
[38]. In an in vitro study using aortic smooth muscle cells, apositive effect of a-tocopherol in reducing CD36 expression
was also evident [3]. Lack of effect of h- or g-tocopherol,
which have comparable antioxidant potential, indicates that
the a-tocopherol acts via a non-oxidant-dependent cell
signalling pathway as first described by Boscoboinik et al.
[2].
In the current study VE supplementation resulted in a
consistent down-regulation in CD36 expression with a
significant 35–70% decrease relative to control animals
between T2 and T4. Although CD36 is thought to be present
in most tissues, embedded in the cholesterol rich domains of
membranes [38], little knowledge exists on the function of
CD36 in liver cell metabolism. In our model, comparison of
plasma triglycerides, total cholesterol and glucose levels in
VE+ animals versus controls did not result in any significant
changes. This result is in line with observations made in
other studies where long-term VE supplementation did not
result in significant changes in blood lipids concentration
[25]. Alterations in blood lipids have been observed in
CD36 null animals and in animals overexpressing the
CD36 gene. However, it is likely that the approximate
50% alteration in CD36 expression in the current study
would not impact total circulating lipid levels, given that the
LDL-receptor family rather than CD36 are primarily re-
sponsible for the receptor-mediated clearance of lipoproteins
from the circulation.
The precise molecular mechanism by which a-tocopher-
ol impacts on CD36 expression is uncertain although an
effect on either PKC or PPAR-g is likely [39]. Alternatively,
this effect may be the result of reduced circulating oxidized
LDL in the VE+ animals compared to the VE animals.
Alpha tocopherol is known to be the main antioxidant
component of LDL, therefore, decreased CD36 expression
in the VE supplemented group may simply reflect lower
circulating oxidized LDL levels.
The consequence of the CD36 changes in the liver is
currently unknown but it may be of greater functional
consequence in other cell types. If the down-regulation of
hepatic CD36 expression observed in the current study was
reflected in other tissues such as the monocyte-macrophage,
it could lead to a decreased accumulation of LDL in the
arterial intima with a potential benefit for the development
of atherosclerosis.
4.3. Coagulation factor IX
Coagulation factor IX (FIX) was found to be down-
regulated in VE+ animals. FIX is a vitamin K-dependent
blood clotting protein, which plays an essential role in the
activity of the intrinsic coagulation pathway. Congenital
deficiency of FIX, haemophilia B, is characterized by the
pronounced tendency of bleeding [40]. On the other hand,
high levels of plasma FIX have been associated with an
increased risk of venous thromboembolism [40]. It is well
known that VE possesses anticoagulant properties and a
number of mechanisms have been proposed such as inhibi-
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VE is thought to act as an antagonist of the vitamin K-
dependent gamma-carboxylase, which is required to activate
enzymes of the blood clotting cascade including FIX [40].
In this regard, it has been suggested that the inhibitory
activity comes from an oxidized form of VE, a-tocopher-
olquinone, which may be present in trace amounts in VE
preparations or formed within the body during VE metab-
olism [41]. In the current study, VE resulted in a moderate
and long-lasting repression of the FIX transcript. In order to
test the relevance of the down-regulation of FIX in response
to VE, activated partial thromboplastin time (APTT) was
assessed, which is a well-accepted screening test for FIX
deficiency. Rats supplemented with VE showed a f 1.2-
fold increase in APTT. Inhibition of APTT is of recognised
value in the prevention and treatment of thromboembolic
events [42]. Overall, our present data support, on a molec-
ular level, the concept that VE may posses some anticoag-
ulant activity. Anticoagulant properties of VE seem to be
partly mediated by a down-regulation of FIX.
4.4. 5-a-Steroid reductase type 1
5-a-Steroid reductase type 1 (5a-R type1) catalyses the
irreversible conversion of testosterone to 5a-dihydrotestos-
terone (5a-DHT), the most potent androgen known. Two
isoenzymes have been identified, namely 5a-R type 1 (5a-
R1) and 5a-R type 2 (5a-R2), which catalyse the same
reaction, but possess distinctive biochemical properties and
different tissue distributions [43]. 5a-R1 is widely distrib-
uted and found in many tissues such as hair follicles,
sebaceous glands and the liver while 5a-R2 is primarily
located in the male reproductive tract such as the prostate,
seminal vesicle and epididymis [44]. Overproduction of 5a-
DHT has been implicated in the progression of benign
prostatic hyperplasia (BPH), prostate cancer, acne, hair loss,
hirsutismus and breast cancer [45–47]. In humans, both
isoenzymes are expressed in the liver while in rats only 5a-
R1 is detected [48]. In the liver, 5a-Rs are believed to exert
a double physiological function, (i) the conversion of
testosterone to 5a-DHT with local and systemic activity
and (ii) the inactivation of excessive blood steroid levels by
the consecutive action of 5a-Rs and 3a-hydroxysteroid
dehydrogenase thereby yielding weaker androgens [49].
In the present study dietary VE was associated with a
consistent transcriptional decrease in 5a-R1 mRNA levels. In
order to test the physiological relevance of this alteration at
the enzyme activity level, we have quantified plasma testos-
terone and 5a-DHT in VE+ versus VE animals. It has
already been shown that VE supplementation significantly
decreased plasma levels of testosterone per se in humans,
however, the underlying mechanism of action remains un-
known. Since most of 5a-DHT is derived from the conver-
sion of testosterone, a decrease in 5a-DHT plasma
concentrations may simply reflect a decrease in the precursor
hormone rather than the inhibition of the enzymatic conver-sion. In order to test for this possibility, plasma 5a-DHT
levels were normalised by plasma testosterone levels, i.e. 5a-
DHT/testosterone, in each animal individually. Importantly,
the normalised 5a-DHT level was significantly decreased in
VE+ animals supporting the hypothesis of a decrease in 5a-
Rs activity due to VE. Epidemiological and intervention
studies have shown a potential positive effect of VE supple-
mentation in the prevention of prostate cancer [46] and in the
relief of BPH symptoms [50]. Several mechanisms of action
have been postulated such as protection of DNA damage by
free radicals, induction of apoptosis, modulation of immune
function and interference with hormone production [51]. The
latter hypothesis was supported by the findings of the ATBC
intervention study where menwho receiveda-tocopherol had
significantly lower serum androstenedione and testosterone
levels than did those who received a placebo [52]. These
findings have been proposed as an explanation for the
reduction in prostate cancer observed in this study. The
current data suggest that dietary VE acts as a suppressor of
5a-R1 isoenzyme at the transcriptional level possibly affect-
ing the conversion of testosterone to 5a-DHT.
4.5. a-TTP and collagen-alpha1
Several genes including a-TTP, collagen-alpha1, alpha
tropomyosin as well collagenase have been reported in the
literature to be vitamin E-sensitve. However, these genes
were not significantly altered in their expression in the
present rat experiment in response to differences in dietary
vitamin E supply.
We found a strong hybridization signal for a-TTP in both
VE- and VE+ livers, however, no significant difference
between the two groups was observed. Our results confirm
those of Shaw and Huang [4]. In animals fed either a VE-
deficient or a VE-adequate diet (100 mg/kg feed VE) for 5
weeks, no difference in a-TTP mRNA expression was
found. Modulation of liver a-TTP expression was only
observed when VE-deficient animals where re-supple-
mented with VE [4]. However, in our study, we did not
re-supplement VE deficient animals.
Chojkier et al. [5] did compare the mRNA levels of
collagen-alpha1 between livers of rats fed either with a VE-
deficient diet or a VE-supplemented diet (>5000 mg/kg feed
VE) for 8 weeks. They found a significant, 70% decrease, in
collagen-alpha1 expression in VE supplemented animals. In
the present study a moderate and consistent decrease in the
expression of the collagen-alpha1 gene between T2 and T4
was observed in the liver of VE+ animals. Collagen-alpha1
showed an average decrease of f 30% (P < 0.05) at time-
points T2 and T4. Since statistical significance was not
found at T3, this gene was not considered for further
analysis. A possible explanation for the differences in the
down-regulation of collagen-alpha1 in response to vitamin
E between our experiment and the results by Chojkier et al.
[5] might be related to differences in the dietary vitamin E
concentration (60 vs. 5000 mg/kg diet).
Biophysica Acta 1689 (2004) 66–74 734.6. Alpha-tropomyosin and collagenase
Azzi’s group was the first to show that VE is able to
modulate the expression of alpha-tropomyosin in rat vascu-
lar smooth muscle cell line. The increase in mRNA expres-
sion was shown to be transient and limited within the first
hours of VE stimulation [7]. Tropomyosin is a muscle-
specific gene and is not expected to be of physiological
relevance in liver. Our mRNA expression data confirm that
tropomyosin is expressed only in trace amount in rat liver.
In addition, short-term, transient changes in gene expression
cannot be detected by our experimental design. Azzi’s group
has demonstrated that VE down-regulates collagenase ex-
pression in human fibroblast cell culture [6]. Also in this
case, the biological relevance of this gene in the liver, if any,
is unknown. In our study its expression level was at the limit
of detection.
L. Barella et al. / Biochimica et5. Conclusion
Advances in expression microarray technology have
allowed us to investigate genes differentially expressed in
rat liver in response to VE, thereby offering the possibility
of more insight into the biological functions of alpha-
tocopherol. Dietary VE leads to a significant up-regulation
of g-GCS, the rate-limiting enzyme in GSH synthesis.
Furthermore, VE induced a down-regulation of coagulation
factor IX and 5-a-steroid reductase type 1 mRNA levels.
These VE-related changes in gene expression were accom-
panied by significant alterations in liver GSH, plasma
activated partial thromboplastin time and normalised 5a-
DHT levels, respectively. Overall, the current study reveals
that dietary VE has important long-term effects on liver
gene expression with potential downstream effects on extra-
hepatic tissues and illustrates the application of genome-
wide expression profiling when investigating the biological
action of essential dietary micronutrients.References
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